• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

我们对艾滋病病毒暴露前预防的成本效益了解多少,它是否负担得起?

What do we know about the cost-effectiveness of HIV preexposure prophylaxis, and is it affordable?

作者信息

Cambiano Valentina, Miners Alec, Phillips Andrew

机构信息

aResearch Department of Infection and Population Health, UCL bDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.

出版信息

Curr Opin HIV AIDS. 2016 Jan;11(1):56-66. doi: 10.1097/COH.0000000000000217.

DOI:10.1097/COH.0000000000000217
PMID:26569182
Abstract

PURPOSE OF REVIEW

The WHO recommends preexposure prophylaxis (PrEP) in populations at substantial risk of HIV. Despite a number of randomized controlled trials demonstrating its efficacy, and several ongoing implementation projects, PrEP is currently only available in a few countries. Modelling studies can provide useful insights into the long-term impact of introducing PrEP in different subgroups of the population. The review summarizes studies that either evaluated the cost-effectiveness or the cost of introducing PrEP, focusing on seven published in the last year.

RECENT FINDINGS

These studies used a number of different types of models and investigated the introduction of PrEP in different settings. Among men having sex with men (MSM) in North America, PrEP ranged from being cost-saving (while benefiting population health) to costing US $160,000/quality-adjusted life-year gained. Among heterosexual sero-different couples, it varied from around US $5000 to US $10,000/disability-adjusted life-year averted, when PrEP was used until 6 or 12 months after the HIV-positive partner had initiated antiretroviral therapy (ART) in, respectively, Uganda and South Africa.

SUMMARY

Future cost-effectiveness studies of PrEP should consider the HIV incidence, the level of uptake, the effect of its introduction on alternative prevention approaches, and the budget impact of rolling it out.

摘要

综述目的

世界卫生组织建议对有高感染艾滋病毒风险的人群进行暴露前预防(PrEP)。尽管多项随机对照试验证明了其有效性,且有几个正在进行的实施项目,但目前PrEP仅在少数国家可用。模型研究可以为在不同人群亚组中引入PrEP的长期影响提供有用的见解。本综述总结了评估PrEP引入的成本效益或成本的研究,重点关注去年发表的七项研究。

最新发现

这些研究使用了多种不同类型的模型,并研究了在不同环境中引入PrEP的情况。在北美的男男性行为者(MSM)中,PrEP从节省成本(同时有益于人群健康)到每获得一个质量调整生命年花费16万美元不等。在异性血清学不同的夫妇中,当分别在乌干达和南非,PrEP在艾滋病毒阳性伴侣开始抗逆转录病毒治疗(ART)后使用6个月或12个月时,避免每一个伤残调整生命年的成本从约5000美元到10000美元不等。

总结

未来PrEP的成本效益研究应考虑艾滋病毒发病率、接受程度、引入PrEP对替代预防方法的影响以及推广PrEP的预算影响。

相似文献

1
What do we know about the cost-effectiveness of HIV preexposure prophylaxis, and is it affordable?我们对艾滋病病毒暴露前预防的成本效益了解多少,它是否负担得起?
Curr Opin HIV AIDS. 2016 Jan;11(1):56-66. doi: 10.1097/COH.0000000000000217.
2
Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria.模拟尼日利亚HIV血清学不一致夫妇联合预防的影响及成本效益。
AIDS. 2015 Sep 24;29(15):2035-44. doi: 10.1097/QAD.0000000000000798.
3
Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.在美国,预防 HIV 暴露前预防措施对受孕的成本效益。
AIDS. 2018 Nov 28;32(18):2787-2798. doi: 10.1097/QAD.0000000000002014.
4
Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.英国男男性行为人群中 HIV 预防的暴露前预防的成本效益:建模研究和健康经济评价。
Lancet Infect Dis. 2018 Jan;18(1):85-94. doi: 10.1016/S1473-3099(17)30540-6. Epub 2017 Oct 17.
5
The preexposure prophylaxis revolution; from clinical trials to programmatic implementation.暴露前预防的变革;从临床试验到项目实施。
Curr Opin HIV AIDS. 2016 Jan;11(1):80-6. doi: 10.1097/COH.0000000000000224.
6
Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York.评估纽约抗逆转录病毒暴露前预防优先排序的影响。
AIDS. 2014 Nov 28;28(18):2683-91. doi: 10.1097/QAD.0000000000000460.
7
Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.中泰两国两所医院男男性行为者中开展暴露前预防的成本及成本效益分析。
J Int AIDS Soc. 2018 Jul;21 Suppl 5(Suppl Suppl 5):e25129. doi: 10.1002/jia2.25129.
8
Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058.2018 年至 2058 年德国预防 HIV-1 感染的暴露前预防的成本效益和预算影响。
Euro Surveill. 2019 Feb;24(7). doi: 10.2807/1560-7917.ES.2019.24.7.1800398.
9
Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.南非用于预防艾滋病毒的注射用暴露前预防药物的成本效益
Clin Infect Dis. 2016 Aug 15;63(4):539-47. doi: 10.1093/cid/ciw321. Epub 2016 May 18.
10
Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.针对乌干达坎帕拉高危血清学不一致夫妇的暴露前预防作为持续使用抗逆转录病毒疗法的桥梁的成本效益。
J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):20013. doi: 10.7448/IAS.18.4.20013. eCollection 2015.

引用本文的文献

1
Machine learning prediction of adolescent HIV testing services in Ethiopia.机器学习预测埃塞俄比亚青少年艾滋病病毒检测服务。
Front Public Health. 2024 Mar 15;12:1341279. doi: 10.3389/fpubh.2024.1341279. eCollection 2024.
2
Implementation and resource needs for long-acting PrEP in low- and middle-income countries: a scoping review.中低收入国家长效预防用 PrEP 的实施和资源需求:范围综述。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26110. doi: 10.1002/jia2.26110.
3
MHepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID.
MHepPrEP:一项多地点多环境随机对照试验的研究方案,针对的是注射吸毒者的整合 HIV 预防和 HCV 护理。
Trials. 2022 Apr 23;23(1):341. doi: 10.1186/s13063-022-06085-3.
4
The case for prevention - Primary HIV prevention in the era of universal test and treat: A mathematical modeling study.预防的理由——普遍检测与治疗时代的原发性HIV预防:一项数学建模研究。
EClinicalMedicine. 2022 Mar 14;46:101347. doi: 10.1016/j.eclinm.2022.101347. eCollection 2022 Apr.
5
Cost-Effectiveness of HIV Retention and Re-engagement Interventions in High-Income Countries: A Systematic Literature Review.高收入国家提高 HIV 患者保留率和重新参与治疗干预措施的成本效益:系统文献回顾。
AIDS Behav. 2022 Jul;26(7):2159-2168. doi: 10.1007/s10461-021-03561-w. Epub 2022 Jan 25.
6
The Cost-Effectiveness of HIV/STI Prevention in High-Income Countries with Concentrated Epidemic Settings: A Scoping Review.高收入国家集中流行地区艾滋病毒/性传播感染预防的成本效益:范围综述。
AIDS Behav. 2022 Jul;26(7):2279-2298. doi: 10.1007/s10461-022-03583-y. Epub 2022 Jan 15.
7
Use of machine learning techniques to identify HIV predictors for screening in sub-Saharan Africa.使用机器学习技术识别撒哈拉以南非洲地区筛查的 HIV 预测因子。
BMC Med Res Methodol. 2021 Jul 31;21(1):159. doi: 10.1186/s12874-021-01346-2.
8
Assessing the use of surveillance data to estimate the impact of prevention interventions on HIV incidence in cluster-randomized controlled trials.评估监测数据在估计以群组为基础的随机对照试验中预防干预措施对艾滋病毒发病率的影响中的应用。
Epidemics. 2020 Dec;33:100423. doi: 10.1016/j.epidem.2020.100423. Epub 2020 Nov 20.
9
National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2014 to 2018 : A Retrospective Cohort Study.美国 2014 至 2018 年艾滋病毒暴露前预防药物支付的全国趋势:一项回顾性队列研究。
Ann Intern Med. 2020 Nov 17;173(10):799-805. doi: 10.7326/M20-0786. Epub 2020 Sep 8.
10
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.品牌替诺福韦艾拉酚胺/恩曲他滨与替诺福韦二吡呋酯/恩曲他滨仿制药用于 HIV 暴露前预防的比较定价:成本效果分析。
Ann Intern Med. 2020 May 5;172(9):583-590. doi: 10.7326/M19-3478. Epub 2020 Mar 10.